It is of note that for cancer patients whose tumor expressing MAGEA4 and MHC I, MAGEA4 vaccines can induce MAGEA4-specific immune responses to activate the CD4+ and CD8+ T cell resulting in the inhibition of tumor cell proliferation [63, 64] (Fig. 6f). This evidence concerns the gene CD4 and neoplasm.